Anondita Medi. moves to reshape its capital structure

The rights issue price is Rs 950 per share, versus the prevailing NSE VWAMPs immediately before the issue-price approval on 26 August 2026:

• 90-trading-day VWAMP: Rs 1,117.10; issue price at a 14.96% discount.
• 60-trading-day VWAMP: Rs 1,142.49; 16.85% discount.
• 10-trading-day VWAMP: Rs 1,077.66; 11.85% discount. ^[1]

Thus, the issue was priced below each stated market-price benchmark, with the discount ranging from 11.85% to 16.85%. The formal terms specify Rs 950 per share, including a Rs 940 premium over the Rs 10 face value. ^[2]

Promoter participation: the promoter group—Anupam Ghosh, Sonia Ghosh and Reshant Ghosh—has committed to subscribe to none of its Rights Entitlements, i.e. 0% subscription to its entitlement. It intends to renounce 100% of its entitlement in favour of the public at large, rather than subscribe to the shares. This replaced the earlier plan to renounce them to specific investors after no such investors were identified or finalised. ^[3]

The practical implication is that the promoters provide no subscription support toward the issue or the 90% minimum-subscription threshold; that burden falls on public shareholders and other eligible investors. ^[4]

The Letter of Offer allocates Rs 25.75 Crores (Rs 2,574.96 lakhs) to short-term working capital and Rs 9.80 Crores (Rs 979.98 lakhs) to general corporate purposes, assuming full subscription. Together, these represent Rs 35.55 Crores, or approximately 41.56% of the Rs 85.55 Crores of net proceeds. The general corporate-purpose allocation is subject to the SEBI ceiling of 25% of gross proceeds; the stated allocation is below that limit. ^[5]

Liquidity bridge

• The latest audited working-capital data, for the year ended March 31, 2026, showed current assets of Rs 67.09 Crores against current liabilities of Rs 14.51 Crores, resulting in a working-capital gap of Rs 52.58 Crores. ^[6]
• The company also had total borrowings of Rs 33.27 Crores at March 31, 2026, including Rs 9.68 Crores of short-term borrowings. This was higher than approximately Rs 27.39 Crores at March 31, 2025. ^[7]
• The business is working-capital intensive and has historically relied mainly on internal accruals and banking limits. The company specifically cites longer collection cycles from government and institutional customers, as well as the need to finance raw materials, inventory and receivables. ^{[6] [8]}

The working-capital tranche therefore provides an equity-funded source for receivables financing, inventory holding and raw-material procurement, reducing the immediate reliance on incremental bank borrowing and internal cash generation. The company’s FY2027 funding schedule assigns the Rs 25.75 Crores rights-issue contribution alongside Rs 10.00 Crores of short-term borrowings and Rs 50.32 Crores of internal accruals against an estimated working-capital requirement of Rs 86.07 Crores. ^[9]

Analytical implication: the rights issue materially eases the liquidity pressure but does not eliminate it. The working-capital proceeds cover approximately 48.98% of the FY2026 audited gap, calculated from the reported figures, while the balance remains dependent on internal accruals and borrowings. The general corporate-purpose component adds flexible funding for subsidiary investment, refurbishment, operating exigencies and ordinary-course expenses, but is discretionary rather than a ring-fenced liquidity solution. ^[10]

Key dates

• Record date: Wednesday, September 2, 2026 — shareholders whose names appear in the depository records or register of members at close of business on this date will determine eligibility for the rights issue. ^[2]
• Issue period: September 9–22, 2026; applications close on the Issue Closing Date, Tuesday, September 22, 2026. ^[11]
• Basis of allotment and allotment: expected on or about Wednesday, September 23, 2026, subject to finalisation of the basis of allotment. ^[11]

Regulatory conditions still relevant to allotment

• Designated Stock Exchange approval of the basis of allotment: the Board’s allotment process is expressly subject to approval of the basis of allotment by the Designated Stock Exchange, which is NSE. ^[12]
• Final NSE listing and trading approvals: the company has already received in-principle listing approval from NSE on August 25, 2026, so that approval is not pending. However, final approvals for listing and trading of the rights shares are still required after allotment. ^[13]
• Trading approval for the Rights Entitlements: the company is required to apply to NSE for the trading approval for the Rights Entitlements under the SEBI ICDR framework. ^[14]
• Other requisite statutory or regulatory approvals, if applicable: the Letter of Offer keeps the issue subject to applicable SEBI, Companies Act, FEMA and other regulatory requirements, including approvals, if any, from RBI or other regulators. It does not identify a specific additional RBI approval as outstanding. ^[15]

Accordingly, the practical gating items are NSE’s approval of the allotment basis and final listing/trading approvals, together with compliance with any other applicable statutory approvals. Until final listing and trading approvals are received, the allotted shares are credited to a temporary ISIN and remain frozen for trading. ^[13]